Chronic Cannabis Smoking, Oxidative Stress and the Pulmonary Innate Immune Response
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-55
SponsorUniversity of Colorado, Denver
About this trial
This study plans to evaluate the effects of chronic cannabis smoking on lung health by evaluating its effects on pulmonary health, lung physiology and alveolar macrophage function.
Eligibility criteria
Qualifiers
Daily or near daily cannabis use (inhaled via joint/cigarette or pipe) equivalent to AT LEAST 20 "joint years" (number of joints/cigarettes per day multiplied by number of years during which cannabis was smoked) by self-report and validated through urine drug screen.
Never or limited exposure to inhaled tobacco products (equivalent to LESS THAN one "pack year" in a lifetime) by selfreport and validated through negative urine cotinine screen.
Capacity to answer screening questions and provide informed consent at time of interview, along with contact information
No cannabis use ever by self-report, and validated through urine drug screen.
Disqualifiers
LESS THAN near daily cannabis use (inhaled via joint/cigarette or pipe) equivalent to LESS THAN 20 "joint years" (number of joints/cigarettes per day multiplied by number of years during which cannabis was smoked) or a negative urine drug screen (for cannabis)
Inhaled tobacco product exposure EXCEEDING one "pack year" or a positive urine cotinine screen
Elevated AUDIT-C score: A 3 item questionnaire to identify subjects with alcohol use disorders.
Prior medical history of liver disease: cirrhosis, total bilirubin > 2.0 mg/dL or albumin <3
Trial design
Treatments tested in this trial
- Bronchoscopy
- Chest X-ray
- Venipuncture
- Intravenous Catheter
Treatment groups
100 Participants
are divided into 2 treatment groupsSponsors and collaborators
University of Colorado, Denver
Lead sponsor
National Center for Advancing Translational Sciences (NCATS)
Collaborator
Source ClinicalTrials.gov